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BRAIN DERIVED NEUROTROPHIC FACTOR: A FORAY INTO PREDICTING NEONATAL
OUTCOMES IN PREMATURE INFANTS.
Vladimir Glinskii, Yue Wu, Qi Li, Sandra Canosa, Irina Buhimschi, Catalin Buhimschi, and
Joseph Madri. Department of Pathology, Yale University School of Medicine, New
Haven, CT.
The need to accurately predict the ability of a prematurely born infant to recover
from hypoxia induced damage associated with prematurity is rooted in our need to
develop better interventions, with fewer side‐effects, with which to treat these
complicated patients. Previous work done in murine models mimicking hypoxia induced
damage and its neurological sequelae have suggested hypoxia induced factor‐1α (HIF‐
1α), and its downstream effector molecules, brain derived neurotrophic factor (BDNF)
and stromal derived factor‐1 (SDF‐1), may play an integral role in protecting the
developing brain from the deleterious effects of low O2. Moreover, a number of single
nucleotide polymorphisms (SNPs) have been identified, which affect the expression of
these proteins on an individual basis. To that end, we hypothesized that BDNF
expression levels gathered from venous cord blood, and genetic analysis for the
presence of the rs6265 and rs1801157 SNPs in the BDNF and SDF‐1 genes could be used
as biochemical and genetic biomarkers to predict short term neonatal outcomes in
premature infants born at Yale New Haven Hospital.
BDNF levels, determined by quantitative ELISA in 23 patients, and the presence
of SNPs, determined in duplicate by restriction fragment length polymorphism assay
and Sanger sequencing in 53 patients, were correlated with the development of a
variety of neonatal outcomes. Our results indicated that although not statistically

significant, the development of bronchopulmonary dysplasia, necrtotizing enterocolitis,
and early onset neonatal sepsis (EONS) trended towards an association with lower cord
blood BDNF levels (p‐values <0.10). Likewise, the presence of the rs6265 SNP appeared
to be protective against the development of culture positive EONS (p < 0.08), while the
presence of rs1801157 SNP appeared to be protective against the development of
clinical EONS. Taken together, these data suggest that while cord blood BDNF levels and
the presence of the rs6265 and rs1801157 SNPs show potential as useful molecular and
genetic biomarkers for predicting outcomes of premature infants, the association
between these factors and neonatal outcomes is not strong enough for the number of
patients examined in this study to provide conclusive results of the utility of these
biomarkers in guiding clinical decision making. Consequently, further research of these,
and other, biomarkers is necessary to better elucidate their usefulness.
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INTRODUCTION
Gestational prematurity (<37 weeks gestation) and low birth weight (< 2500g) in
newborns is associated with an increased risk for a variety of complications in multiple
organ systems, which results in a significant increase in the morbidity and mortality of
these infants when compared to their full term counterparts (1). Of these complications,
disorders of the developing nervous system are of particular significance, and include
deficits ranging from cerebral palsy and intellectual disability to more subtle disabilities
such as ADHD and social‐emotional difficulties (2). As medical science progresses, the
incidence of preterm birth has increased by more than 30% over the past several
decades, from 9.4% in 1981 to over 12.5% in 2004 (1). This increase is partially due to
our improved abilities at keeping alive preterm infants who would not have survived
past the perinatal period a decade earlier. Interestingly, one prospective cohort study
done in Dorset, England showed an 11% increase in the survival to discharge from the
neonatal intensive care unit of premature infants born at either 24 or 25 weeks
gestation from 36% in 1994 to 47% in 2000‐2005 (3). However, while the decline in the
premature infant mortality rate in recent years is encouraging, the rising emotional,
monitory, and social costs associated with taking care of patients afflicted with these
adverse outcomes, as they develop and grow into adulthood, presents a number of
significant challenges.
The incidence and severity of adverse neurodevelopmental outcomes has been
shown to be strongly associated with the gestational age and birth weight of premature
infants (4, 5). These abnormalities are thought to be, at least in part, secondary to
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cerebral hypoxemia resulting from apnea and respiratory distress syndrome which is
prevalent in over two‐thirds of very low birth weight (< 1500g) preterm infants (6, 7).
The extent to which the damage from these insults manifests itself in later neurological
development, however, varies widely (8). Further, multiple studies have demonstrated
that the observed variations in responses to sublethal hypoxia associated with
premature birth can be mimicked in CD‐1 and C57BL6 mouse strains using specific
insults (9‐11).
Using such models, mice reared under hypoxic conditions have shown an
increased expression of genes subserving presynaptic function, and a concomitant
decrease in expression of genes involved in synaptic maturation, synaptogenesis, and
glial differentiation (12). These effects, combined with the elevated rates of neuronal
cell death seen in hypoxic brain injury, are thought to contribute to the deleterious
effects of low O2 (13). Consequently, recovery from such an insult is likely to be, at least
in part, dependent upon replacement of lost neurons by stimulation of neuronal stem
cells (NSCs) and renewed synaptogenesis. A differential response from known regions of
neurogenesis such as the subventricular zone (SVZ) and the subgranular zone (SGZ)
could underlie the variability of recovery to hypoxia induced damage that is observed in
premature infants. Importantly, proper functionality within neurovascular
compartments of SVZ and SGZ including neuronal regeneration, NSC self‐renewal,
differentiation and guidance is inseparable from the status and function of
microvasculature. Effects of endothelial cells lining the blood vessels in the SVZ and SGZ
are indispensable in the regulation of stem cell self‐renewal and neurogenesis.
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Endothelial cells reside in close proximity to clusters of proliferating neurogenic cells,
provide attachment points for the latter, and share with NSCs multiple signaling
pathways induced by VEGF, BNDF, and/or SDF‐1/CXCL12 that mediate both
angiogenesis and neurogenesis. Consequently, studies showing that neurogenesis and
angiogenesis share several common signaling pathways, imply that neurogenic cells and
endothelial cells in the SVG and SGZ could have a reciprocal effect on one another
Over the last decade our group has shown the uncoupling of the tightly
controlled involution/ stabilization of the SVZ vasculature that occurs following
premature delivery in animal models (14, 15). This decoupling results in the involution
of the SVZ vasculature without vascular stabilization. The resulting disruption in the
normal formation of basement membranes, tight junctional complexes and vessel wall
envelopment by glial and pericyte cell processes in turn leads to increased rates of
intraparenchymal and interventricular hemorrhage (16). More recently, SVZ and SGZ
vasculature has been shown to not only participate in promoting a neurogenic
environment, but also participate more directly in guiding newly generated neuronal
precursor cells along the blood vessels to areas of ischemic damage (17).
The molecular mechanism of SVZ vascular stabilization and increased
neurogenesis is thought to, at least in part, involve the HIF‐1α signaling cascade, and its
downstream effector molecules, including BDNF, VEGF, and SDF‐1. Activation of HIF‐1α
in response to hypoxic insult results in the initiation of a complex cross‐talk between
neuronal cells and vascular endothelial cells within the neurovascular niche, which
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contributes to neural stem cell activation, induction of angiogenesis, and microvascular
stabilization (18). Hypoxia‐resistant CD‐1 pups reared under 9.5% O2 until post‐natal day
P11 showed increased expression of BDNF, VEGF, and SDF‐1 in whole brain lysates, as
well as increased NSC proliferation both in vivo and in vitro, as compared to their
C57BL6 counterparts. Further, C57BL6 NSCs co‐cultured with brain endothelial cells and
treated with rBDNF, rVEGF, and rSDF‐1 showed enhanced NSC proliferation to levels
equal to those of CD‐1, and conversely, sequestration of these factors in CD‐1 cultures
blunted NSC proliferation rates to those of C57BL6, suggesting that it is the increased
responsiveness of HIF‐1α to hypoxic insult by endothelial cells and neural stem cells in
the SVZ of the CD‐1 mouse strain, and the subsequent induction of downstream
signaling pathways involving BDNF, VEGF, and SDF‐1, that is thought to underlie CD‐1’s
resilience to low O2 (9, 18).
Based on this information, it is reasonable to hypothesize that systemic (serum)
levels of HIF‐1α downstream effector proteins such as BDNF, VEGF, and SDF‐1 could
potentially serve as biochemical markers reflecting the neurovascular response of
prematurely born neonates to a hypoxic insult and help predicting the risk of developing
related complications associated with the premature birth in these patients.
Further, there is an evolving body of evidence in a current literature strongly
suggesting that in various pathologic conditions associated with changes in BDNF, SDF‐1,
and VEGF levels, such changes could be linked to genetic variations defined by single
nucleotide polymorphism (SNP) mutations within their respective genes. For example,
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the rs6265 SNP, a G to A mutation of the BDNF gene at the nucleotide 196, producing a
val66met amino acid substitution in the 5’ pro‐BDNF region, has been shown to affect
the protein’s intracellular processing and secretion via the mechanism involving
alterations in pro‐BDNF interaction with sortilin, a protein responsible for sorting BDNF
into the regulated secretory pathway (19, 20). Similarly, the association between the
rs1801157 polymorphism, a G801A mutation located in the 3’ untranslated region of the
CXCL12/SDF‐1 gene, and susceptibility to several different diseases correlated with
changes in SDF‐1 levels has been proposed (21‐23). Thus, SNP mutations within the
genes encoding for the HIF‐1α downstream effector proteins such as BDNF, VEGF, and
SDF‐1 could potentially play a role in underpinning the ability of prematurely born
patients to resist and/or recover from hypoxic insults and related complications. If that
is the case, then such SNPs could potentially serve as genetic markers that may help to
identify the patients that are at a greater risk of developing complications associated
with premature birth and, perhaps, even predict their response to therapeutic
interventions.
In this study, we begin the search for biochemical and genetic markers
associated with neurovascular complications in premature newborns by investigating
the potential relationship between systemic BDNF protein levels and the presence of
rs6265 (val66met) and rs1801157 (G801A) SNP mutations in BDNF and SDF‐1 genes
respectively with a range of neonatal complications in a cohort of 53 premature
singleton neonatal patients born to mothers at Yale New Haven Hospital.

6
METHODS

Cord blood acquisition
Cord blood samples used for this study were generously provided by Dr. Irina
Buhimschi. The protocols for acquiring fetal cord blood and associated patient
information was approved by the Yale University Human Investigational Committee, and
all mothers provided written and informed consent. Fetal cord blood was acquired from
a cohort of 180 consecutive preterm singleton newborns born to mothers at Yale New
Haven Hospital between May 2004 and September 2009, as well as 19 healthy non‐
laboring women undergoing elective cesarean delivery at term. Gestational age of
infants was calculated by time since last menstrual period and ultrasound evaluation
prior to 20 weeks gestation. Exclusion criteria for maternal enrollment included: chronic
medical conditions (i.e. hypertension, diabetes, thyroid disease), HIV, hepatitis or other
viral infections, fetal structural abnormalities or fetal heart rate abnormalities requiring
immediate intervention. Mothers of all preterm infants underwent amniocentesis to
rule out intra‐amniotic infection and/or inflammation prior to delivery using standard
clinical, biochemical, and microbiological amniotic fluid tests including glucose
concentration (cut‐off of ≤15 mg/dL), lactate dehydrogenase activity (LDH, cut‐off ≥419
U/L), white blood cell count (WBC, cut‐off ≥50 cells/mm3), Gram stain and
microbiological cultures for aerobes, anaerobes, Ureaplasma, and Mycoplasma species,
as described in (24). Cord blood was acquired by sterile puncture of the umbilical vein
after delivery, centrifuged for 10 min (1,000g, 4°C), alquioted and stored at ‐80°C. Fifty‐
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three samples from this larger cohort were then chosen at random for further SNP
analysis.
Genomic DNA extraction/purification
Genomic DNA (gDNA) was purified from fetal cord blood by use of DNeasy Blood
and Tissue Kit (Quiagen, Cat# 69506) according to manufacturer’s instructions. Briefly,
50μL of cord blood was treated with 20μL of proteinase K, brought to a volume of 220μL
with PBS buffer solution. 200μL of Buffer AL were then added to each sample, vortexed,
and incubated at 56°C for 10 min. An additional 200μL of 100% ethanol was added to
each sample, and the samples were all loaded into DNeasy Mini spin columns to bind
DNA. Samples were centrifuged at 8000rpm for 1 min, and the remaining contaminants
were washed out using Buffers AW1 and AW2, and spun dry at 14000rpm for 3 min.
Genomic DNA was eluted from the spin columns in 200μL of Buffer AE elution buffer,
provided in the kit. The resultant eluent was stored at ‐20°C.
Genomic DNA quantification
Quantification of gDNA purified from cord blood RBCs was done by means of
densitometry against a standard curve. 2μL of each gDNA sample was mixed with 10x
DNA gel‐loading dye and distilled water (ddH2O) to a total volume of 10μL, and loaded
onto a 1% agarose gel made with TAE buffer solution and stained with SYBR Safe DNA
gel stain (Invitrogen, Cat# S33102). A standard curve was generated by serial dilutions of
λ DNA to achieve concentrations of 20ng/mL, 10ng/mL, 5ng/mL, 2.5ng/mL, and
1.25ng/mL and loaded onto the gel. The gel was run at 80V for 100min and visualized in
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the ChemiDoc imaging system (BioRad). Densitometry was performed using Quantity
One software (ver 4.6.9), and final gDNA concentrations were quantified in relation to
the standard curve.
PCR (BDNF, SDF‐1)
Gene amplification was performed using the Advantage 2 PCR Kit (Clontech, Cat#
639207) according to manufacturer’s instructions. PCR reactions were set up containing
25ng of gDNA from each sample, and a master mix consisting of 2.5μL 10x SA Buffer,
0.5μL of 50x dNTP, 0.5μL of 10μM Forward Primer, 0.5μL of 10μM Reverse Primer, and
0.5μL of 50x Advantage 2 Polymerase Mix. Primer sequences and expected amplicon
sizes can be seen in Table A. Each sample was then brought up to a total volume of 25μL
with PCR grade water and put into a thermal cycler. BDNF thermal cycler settings were
to heat the samples to 95°C for 5 min, 35 cycles of 95°C for 30 sec, 60°C for 30 sec, and
72°C for 30 sec, followed by cooling the samples to 72°C for 10 min, and then maintain
samples at 4°C indefinitely. SDF‐1 thermal cycler settings were to heat the samples to
94°C for 8 min, followed by 35 cycles of 94°C for 30 sec, 62°C for 1 min, and 72°C for 1
min, followed by cooling the samples to 72°C for 5 min, and then maintain the samples
at 15°C indefinitely.
Amplicon extraction/purification
All PCR products were visualized on a 2% GPG agarose gel made with TAE buffer
solution and stained with SYBR Safe DNA gel stain (Figs 1a and 2a). Each 25μL PCR
sample was mixed with 2μL of 10x DNA gel‐loading dye and run at 100V for 45 min. A
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100bp DNA ladder was also run with each gel to verify the expected size of each
amplicon. PCR products were visualized using the ChemiDoc imaging system, and then
extracted using the QIAquick Gel Extraction Kit (Quiagen, Cat# 28706) according to
manufacturer’s instructions. Briefly, each sample was carefully excised from the agarose
gel with a clean scalpel under a UV light, ensuring a clear visible margin of the gel in
between samples. The samples were then treated with Buffer QG and incubated for
10min at 50°C, until the gel had completely dissolved. Isopropanol was added to each
sample to increase yield of DNA fragments, and each sample was loaded onto a
QIAquick spin column and centrifuged for 1min at 13000 RPM. Another 500μL of Buffer
QG was added to each step to ensure the removal of all traces of the agarose gel, and
the centrifugation repeated. Each sample was then washed with 750μL of Buffer PE, and
eluted with 50μL of Buffer EB, provided in the kit. The eluate was stored at ‐40°C.
Amplicon Quantification
Quantification of PCR product was done by means of densitometry against a
standard curve. 2μL of each PCR product was mixed with 10x DNA gel‐loading dye and
ddH2O to a total volume of 5μL, and loaded onto a 2% GPG agarose gel made with TAE
buffer solution and stained with SYBR Safe DNA gel stain. A standard curve was
generated by serial dilutions of a 1Kb DNA ladder (Invitrogen, Cat# 15615‐024) to
concentrations of 80, 40, 20, 10, and 5 ng/μL. 5μL of each dilution was loaded onto the
gel, resulting signal intensities corresponding to 40, 20, 10, 5, and 2.5ng, respectively, to
be seen at the 1636‐bp band. The gel was run at 75V for 60min and visualized in
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ChemiDoc imaging system. Densitometry was performed using Quantity One software,
and final amplicon concentrations were quantified in relation to the standard curve.
BDNF RFLP Analysis
Restriction fragment length polymorphism analysis of the BDNF amplicon was
carried out with the use of the AflIII (New England BioLabs, Cat# R0541S) and PmlI (New
England BioLabs, Cat# R0532S) restriction endonucleases. 50ng of each sample was
mixed together with 5u of AflIII and 5u of PmlI, in BSA, NEBuffer 2, and ddH2O, to a final
reaction volume of 25μL. The reaction was run overnight at 37°C. Each sample was then
loaded onto a 4% GPG agarose gel made with TAE buffer solution and stained with SYBR
Safe DNA gel stain, and run alongside 100bp DNA ladder (Invitrogen, Cat# 15628‐019) at
75V for 90min. The gel was visualized using ChemiDoc imaging system, and the resulting
banding pattern was evaluated to determine the identity of the SNP present (Fig 1b).
SDF‐1 RFLP Analysis
Restriction fragment length polymorphism analysis of the SDF‐1 amplicon was
carried out with the use of the NciI (New England BioLabs, Cat# R0196S) restriction
endonuclease. 50ng of each sample was mixed together with 40u of NciI in NEBuffer 4
and ddH2O, to a final reaction volume of 25μL. The reaction was run overnight at 37°C.
Each sample was then loaded onto a 4% GPG agarose gel made with TAE buffer solution
and stained with SYBR Safe DNA gel stain, and run alongside 100bp DNA ladder
(Invitrogen, Cat# 15628‐019) at 75V for 90min. The gel was visualized using ChemiDoc
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imaging system, and the resulting banding pattern was evaluated to determine the
identity of the SNP present (Fig 2b).
Amplicon DNA Sequencing
DNA sequencing of PCR products was done by the Sanger method at the Yale
Keck DNA Sequencing Facility. BDNF sequencing was done in duplicate, using the PCR
forward primer and a separate BDNF reverse sequencing primer, which was used to
meet Keck primer specifications. SDF‐1 sequencing was performed with the PCR forward
primer only. Samples were prepared by mixing 20ng of amplicon per 200 base pairs to
be sequenced (resulting in 22.3ng for BDNF samples, and 54.3ng for SDF‐1 samples)
with 2μL of 4μM DNA primer and ddH2O to a total volume of 18μL. Samples were then
plated onto a 96‐well plate and sent to the Keck DNA Sequencing Facility. The resulting
sequences were analyzed using Geneious (ver 4.8, Biomatters) software (Fig 1c‐d, Fig 2c‐
d).
Quantitative ELISA determination of BDNF Levels
All cord blood BDNF levels were acquired from platelet poor plasma samples by
Dr. Yue Wu using the DuoSet ELISA Development System (R&D Systems,
[http://www.rndsystems.com]). All assays were performed in triplicate using the
manufacturer's recommended buffers, diluents, and substrates, according to
manufacturer instructions. The ELISAs were read using an automated microplate reader
(Wallac Victor). The BDNF concentrations were corroborated with total plasma protein
concentration and reported as pg/mg.
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Acquisition of Clinical Data
All clinical and diagnostic patient information was gathered for an alternate
study (24), and was generously provided by Dr. Irina Buhimschi, in de‐identified form,
for correlation analysis with the SNP and protein expression data. Diagnoses of clinical
short‐term neonatal outcomes were done by trained physicians in accordance with
clinical guidelines at Yale New Haven Hospital.
Statistical Analysis
Statistical analysis was done using SigmaPlot statistical software (ver 12.0, Systat
Softare). Normality testing was performed using the Shapiro‐Wilk test, with α‐value of
0.05 used as threshold for normal distribution. Data that was not normally distributed
was analyzed using Mann Whitney Rank Sum test. Normally distributed data was
evaluated using a 1‐tailed student t‐test. Comparison of categorical data between two
groups was analyzed using Fisher’s exact test, while comparisons of multiple groups
were done using Chi‐square analysis. Statistical significance was assumed with p‐values
<0.05, while trends towards significance were assumed for p‐values <0.10.
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RESULTS
BDNF G196A Allele and Clinical Outcomes
The presence of the BDNF G196A SNP was determined in duplicate using both
restriction fragment length polymorphism analysis and direct Sanger sequencing. Of the
fifty three samples that were analyzed, ten of them were found to have the A allele in
position 196 of the BDNF gene. This frequency of 18.9% was similar to the previously
published frequency of 22.9%. One out of the fifty three samples tested resulted in an
equivocal RFLP signal, and the sample was recorded as being negative for the G196A
SNP based on Sanger sequencing alone.
Of the maternal characteristics analyzed, no statistically significant differences
between mothers who had children with the G allele vs mothers who had children with
the A allele in the BDNF gene were found (Table B). Maternal characteristics analyzed
included maternal age, gravidity, parity, and race, whether or not the mother clinically
required medical interventions such as steroids, antibiotics, tocolysis, magnesium
sulfate, or progesterone throughout her pregnancy/ the peri‐partum period, and the
outcomes of placental histological analysis screening for evidence of chorionic plate
inflammation, amnionitis, choriodeciduitis, or funisitis. The median age of mothers with
a child having the A (vs G) allele was 31 (vs 27), median gravidity 3 (vs 3), and median
parity 1 (vs 1). Of the patients analyzed 34% were Caucasian, 42% African American,
17% Hispanic, and 8% Other, with no statistically significant difference in the racial
classification of mothers between the two different groups.
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The median Apgar score at 1 and 5 min after birth was 6.5 and 8, respectively,
for infants positive for the G196A SNP, compared to 6 and 8, respectively, for infants
negative for it. This difference was not found to be statistically significant. The
difference in the median gestational age for infants with the A‐allele (30.15 weeks vs
26.2 weeks) and the median weight of infants with the A‐allele (1460g vs 930g) at the
time of birth, however, though not statistically significant, did trend towards significance
with p‐values of <0.1. Further analysis of the presence of other known neonatal
complications revealed no statistically significant difference between the two groups,
with incidence rates for interventricular hemorrhage of 11% (vs 24%),
bronchopulmonary dysplasia 10% (vs 18%), necrotizing enterocolitis 10% (vs 12%),
retinopathy of prematurity 22% (vs 36%), periventricular leukomalacia 11% (vs 10%),
clinical early‐onset neonatal sepsis 50% (vs 33%), and death of 0% (vs 10%), all with p‐
values >0.45. The overall presence of any adverse outcome for infants with the G196A
polymorphism was 30% compared to the 40% present in the control group, with a p‐
value of 0.722 (Table C).
SDF‐1 G801A Allele and Clinical Outcomes
The presence of the SDF‐1 G801A SNP was also determined using restriction
fragment length polymorphism analysis and confirmed with direct Sanger sequencing.
Thirteen of the fifty three patients analyzed were positive for the G801A SNP, resulting
in a 24.5% frequency rate of the A‐allele (as compared to the published frequency of
20.7%). One out of the fifty three samples tested showed a discrepancy between the
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RFLP analysis results and the sequencing results. However, due to the clearly visible
presence of multiple bands on the RFLP gel, suggesting the presence of A‐allele, that
sample was recorded as positive for the G801A SNP.
As with the G196A SNP analysis, no statistically significant demographic
differences between mothers of infants positive or negative for the G801A SNP were
found. The median age, gravidity, and parity for the subset of mothers of infants with
the C‐allele were 29.5, 3, and 1, respectively, while the median age, gravidity, and parity
for the subset of mothers of infants with the T‐allele were 25, 2, and 1, respectively.
Likewise, there was also no statistically significant difference in the number of mothers
who received any steroids, antibiotics, tocolytics, magnesium sulfate, or progesterone
between the two groups (Table D). Subgrouping of patients based on the presence of
the G801A SNP did reveal a relatively lower incidence rate of stage 2‐4 choriodeciduitis
(61.5% vs 89.7%, P<0.04), as well as a relatively lower incidence rate of chorionic plate
inflammation (53.8% vs 79.5%, p <0.09), in mothers giving birth to infants with the A‐
allele (Table E). No readily apparent difference was observed in the incidence rates in
this sub‐grouping of mothers with respect to amnionitis and funisitis.
The median Apgar score at 1 and 5 min after birth was 6 and 8 for infants
positive for the G801A polymorphism, compared to 8 and 8 for infants negative for the
polymorphism, with a p‐value of 0.7 and 0.8, respectively. The median gestational age at
the time of delivery was 26.8 weeks and 26.2 weeks, and the median birthweight 1025g
and 920g, for infants with the G‐allele and the A‐allele, respectively. Of the immediate
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neonatal complications that were looked at, infants with the G‐allele had a 45%
incidence rate of clinical early‐onset neonatal sepsis vs 8.3% in infants with the A‐allele,
p<0.05. Other complications, including interventricular hemorrhage (22.5% vs 18.2%),
bronchopulmonary dysplasia (13.5% vs 27.3%), necrotizing enterocolitis (12.5% vs 8.3%),
retinopathy of prematurity (30% vs 45.5%), periventricular leukomalacia (10% vs 9.1%),
and death (7.5% vs 8.3%) did not show any significant difference between the two
groups (Table E). Overall incidence rate of any adverse outcome was 35% for infants
with the C‐allele, and 50% for infants with the T‐allele, with a p‐value of 0.50.
BDNF Protein Expression Data
BDNF protein expression data was gathered by Dr. Yue Wu using a quantitative
ELISA assay on cord blood samples from a subgroup of 23 patients. Protein levels were
then subdivided with respect to the presence or absence of a number of neonatal
complications, and analyzed using 1‐tailed student t‐test. Of these neonatal
complications, death was the only one that yielded statistically significant differences in
BDNF levels between the two groups, with a mean protein level of 183.43pg/mg in
patients who died prior to discharge from the NICU as compared to 105.33pg/mg in
those who survived (Table F). Presumed early‐onset neonatal sepsis, which was
determined to be as either high (>70%) or low (<20%) level of probability of intra‐
amniotic infection and/or inflammation (IAI) by means of Bayesian latent‐class analysis
of a variety of factors, including elevated haptoglobin and haptoglobin‐related protein
immunoreactivity (Hp&HpRP), cord blood IL‐6 levels, and a variety of other neonatal
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hematological indices, trended towards significance. Of these two groups, the average
BDNF level for infants classified as highly likely to be exposed to IAI was 104.29pg/mg,
while BDNF levels for those classified unlikely to have been exposed was 147.33pg/mg,
p‐value 0.089. While segregating the patients by clinically confirmed EONS, which was
defined as infants with presumed EONS on the basis of hematological indices plus either
the presence of clinical symptoms and/or positive blood cultures at ≤ 72 hours after
birth, resulted in further trend towards significance, with patients positive for clinical
EONS resulting in mean BDNF expression levels of 95.66pg/mg, while those classified as
negative for clinical EONS reached 141.33pg/mg, with a p‐value of 0.051. Likewise, the
presence of bronchopulmonary dysplasia or necrotizing enterocolitis also yielded
differing BDNF expression levels that trended towards significance, with those positive
for either disease averaging 69.2pg/mg or 74.48pg/mg, respectively, while those
negative for the disease averaging 114.36pg/mg or 124.16pg/mg, respectively, with a p‐
value of 0.079 and 0.089. Correlations of BDNF levels with the development of
interventricular hemorrhage, retinopathy of prematurity, or periventricular
leukomalacia, however, did not yield any statistically significant differences in
expression.
Of note, although analyzing the patients on the basis of the presence or absence
of IVH alone did not list statistically significant results, separating the patients into three
distinct groups of: No IVH/no EONS, no IVH/positive EONS, or positive IVH, showed
statistically significant differences in BDNF expression levels between the no IVH/no
EONS and the no IVH/positive EONS groups, with a mean of 157.71pg/mg and 84.65
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pg/mg, respectively, p‐value <0.01, and a trend towards significance between the No
IVH/no EONS, and positive IVH groups, with a mean of 157.71pg/mg and 109.46pg/mg,
respectively, p‐value <0.10 (Fig 3).

19

DISCUSSION
Searching for genetic and biochemical markers, which could help to identify
patients who are at a greater risk of developing complications associated with
premature birth, is an important goal of modern neonatal medicine. Indeed, with the
advent of medical technology and falling infant mortality rates, increasing numbers of
premature infants are surviving past the perinatal period. However, as the minimum
gestational age of premature infants surviving child birth decreases, the number of
neonates with serious complications being cared for continues to grow. In 2009, of the
4,130,000 live births, 12.18% were born prior to 37 weeks gestation (with 2% <32 weeks
gestation), 8.16% were low birth weight (<2500g), and 1.45% were very low birth weight
(<1500g). Simultaneously, the neonatal mortality rate dropped from 4.29 deaths per
1000 live births in 2008 to 4.19 in 2009, resulting in a significant number of very low
birth weight premature infants requiring medical attention (25). Of the possible
complications in this population group, the most common is respiratory distress with an
incidence rate of 93%. Other possible complications include retinopathy of prematurity
(59%), bronchopulmonary dysplasia (42%), necrotizing enterocolitis (11%),
intraventricular hemorrhage (IVH, 16%), and periventricular leukomalacia (3%) (26).
Long term consequences of decreased oxygenation of end organs, and more specifically
the neonatal brain, range from cerebral palsy and intellectual disability to more subtle
disabilities such as ADHD and social‐emotional difficulties, resulting in an estimated cost
of 370 million dollars per year in special education costs alone (27).
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Although significant advances have been made in both preventing and treating
negative outcomes associated with premature birth, these interventions are not without
side‐effects. Infants who are not able to maintain proper oxygen saturation levels, or
who become acidotic, are intubated and mechanically ventilated to help reverse
hypoxemia and prevent long term neurocognitive sequelae. Though necessary,
mechanical ventilation can result in permanent lung injury through a variety of means
including overdistension, barotrauma, and infection, resulting in damage to the airway
epithelium, destruction of the alveoli, and fibrosis of lung tissue secondary to
inflammation. It is estimated that somewhere between 30‐40% of very low birth weight
infants suffer from chronic lung disease (28). Moreover, increased oxygen delivery to
end organs in the periphery may result in oxygen toxicity stemming from generation of
reactive oxygen species with subsequent cellular injury and cell death (29). Additionally,
free radical species generated from both hypoxia of respiratory distress and hyperoxia
of mechanical ventilation serve to perturb angiogenesis throughout more sensitive
areas of the body via its effect on the hypoxia induced factor‐1alpha (HIF‐1α) signaling
pathway and its downstream effector molecules such as vascular endothelial growth
factor (VEGF) and nitric oxide (NO). Such perturbations serve a key role in pathogenesis
of neonatal complications such as retinopathy of prematurity, and may also contribute
to the negative neurodevelopmental outcomes seen in very low birth weight premature
infants described above (9, 18, 30, 31).
The efficacy of current first‐line treatments as well as their optimal
regimentation and dosing are also in need of improvement. A recent study in China
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revealed that despite administration of standard of care therapy, including
administration of exogenous surfactant and different conventional mechanical
ventilation modalities, 31% of neonates who developed respiratory distress syndrome
did not survive (32). Exogenous corticosteroid administration prior to delivery of
premature infants, the cornerstone for managing preterm infants, has greatly improved
neonatal morbidity and mortality. However, despite their clear benefits, more than 60%
of affected premature infants go on to develop respiratory distress syndrome and more
than 50% experience cerebroventricular hemorrhage even with appropriate
intervention. Moreover, antenatal corticosteroids have shown no statistically significant
difference in the rates of development of many long term side effects of prematurity,
such as decreased lung function, behavioral/learning difficulties, or intellectual
impairment (33).
Taken together, this data illustrates the need for not only the development of
novel interventions to prevent and treat immediate complications of low birth weight
and prematurity, but also determine which individuals would derive more benefit from
current interventions than harm from their associated side‐effects. The efficacy of such
new treatments, however, is difficult to evaluate due to the complexity of factors
involved in multiple disease processes associated with prematurity, and an infant’s
recovery from them. Consequently, there would be great utility in being able to
delineate patients who are at greatest risk for developing significant short term and long
term morbidities resulting from hypoxemia and respiratory distress, from those who
would naturally return to their baseline without treatment, as early as possible. One
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potential approach for accomplishing such a feat is through the identification of novel
genetic and molecular biomarkers, which could help predict an individual’s response to
hypoxia.
The underlying ability of tissues extremely sensitive to levels of oxygenation,
such as the brain, to recover from hypoxic damage is thought to lie in the neurogenesis
that occurs in response to chronic sublethal oxygen deprivation. Murine models
mimicking chronic hypoxia have been used to gain insights into this process. Mice
reared under hypoxic conditions (9.5‐10.5% O2) for 8 days starting at post natal day
three (P3) showed a 24% decrease in brain weight, and a concomitant 30% loss of
neurons in the cerebral cortex, as compared to their normoxic counterparts (34). This
difference in brain weight, however, completely reversed within 1 week of returning to
normoxic conditions, with no apparent difference in the density of neuronal cell bodies
on immunostaining. By 31 days of recovery, the only discernible difference between the
hypoxic and normoxic reared mice was morphological, with a thinning and decreased
regularity in the array of the pyramidal cell dendritic arbors in the cerebral cortex.
Intraperitoneal injection of a thymidine analog bromodeoxyuridine (BrdU) at varying
time points revealed a 40% increase in BrdU‐labeled neural cells in the cerebral cortex
of hypoxic‐reared mice one month after BrdU incorporation, as compared to their
normoxic counterparts. Moreover, there was a greater than two‐fold increase in BrdU‐
labeled cells expressing neuronal markers within the SVZ in mice recovering from
hypoxia within 1 week of return to normoxic conditions, suggesting that the recovery
from hypoxia induced brain damage is at least in part dependent upon activation of
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increased neurogenesis to compensate for neuronal losses following prolonged
decreased oxygenation (34). However, even in this mouse model, as in human disease,
the extent of recovery from hypoxia‐induced damage varied significantly from one
individual to the next.
To investigate this further, our lab has characterized the response to chronic
hypoxia between two different mouse strains, which exhibit differing levels of abilities
to recover from such an insult, in hopes of elucidating key proteins that are integral to
initiating this response. Two strains of mice (CD‐1 and C57BL/6), were reared under
both hypoxic and normoxic conditions as described in (34). It was found that while CD‐1
pups were able to survive a 30‐day exposure to hypoxia, C57BL/6 pups expired at day 13
under similar conditions. Pups were thus sacrificed at postnatal day P11, while both
strains were still viable, for further analysis. Examination of the difference in hepatic
extramedullary hematopoiesis (EMH) between the two strains, a known response to
chronic hypoxia, showed a 3.4‐fold induction in hepatic EMH in the CD‐1 strain as
compared to CD‐1 mice raised under normoxic conditions, with no such appreciable
increase in EMH observed in the C57BL/6 mouse strain. Comparison of hepatic EMH
between strains both raised under normoxic conditions showed no appreciable
difference in activation (9). Assaying the difference in SVZ NPC proliferation between
the two strains using BrdU labeling of nestin‐positive cells showed a baseline increase in
the percent of nestin‐positive cells that were also BrdU‐positive in the CD‐1 pups
(30.2%) vs. the C57BL/6 pups (20.6%), when raised under normoxic conditions. This
difference further widened when comparing mice raised under hypoxic conditions, with
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CD‐1 pups exhibiting 21.2% BrdU/nestin double‐labeled cells vs. only 8.2% in C57BL/6
pups, thereby supporting the notion that CD‐1 pups’ resistance to hypoxia is at least in
part due to an increased neurogenic response. Similarly, staining tissue from the SVZ
areas of each mouse strain with anti‐PECAM‐1 antibodies revealed both a higher
baseline microvascular density in CD‐1 pups as compared to C57BL/6 pups, and a higher
final microvascular density, when exposed to normoxic and hypoxic conditions,
respectively (9).
Prior work done by our group with neural stem cells and brain endothelial cells
(BECs) in cell culture has demonstrated a complex cross‐talk that occurs between the
two cell types involving BDNF and VEGF molecules associated with NSC proliferation and
vascular tube formation. In these experiments either co‐culturing NSCs with BECs or
growing BECs in the presence of NSC‐conditioned media both resulted in the formation
of branching endothelial cell microtubular structures (illustrative of in vitro
angiogenesis) in contrast to a BEC mono‐layer growth that occurs in the absence of NSC‐
derived soluble factors. At the same time, NSCs grown either in co‐culture conditioned
media or in direct co‐culture with BECs exhibited a significant increase in number and
size of NSCs as compared to NSCs grown in NSC media alone. As expected, western blot
analysis of BEC cell lysates revealed increased phosphorylation of the brain endothelial‐
derived VEGFR2 receptor in response to soluble factors secreted by NSCs compared to
that induced by BEC‐conditioned media. The examination of BDNF and VEGF protein
expression levels using ELISA revealed a relatively low baseline expression of both BDNF
and VEGF in BEC mono‐cultures, a relatively high baseline expression of VEGF and a low
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baseline expression of BDNF in NSC mono‐cultures, significantly increased BDNF and
VEGF levels in BECs isolated from NSC‐BEC co‐cultures (compared to protein levels from
BEC monocultures), and no changes in VEGF and BDNF levels in NSCs isolated from NSC‐
BEC co‐cultures (compared to protein levels from NSC monocultures). Furthermore,
treatment of NSC‐BEC co‐cultures with sFlt‐1 and sTrkB, which serves to sequester VEGF
and BDNF respectively, results in dramatic blunting of vascular tube formation, which is
in turn rescued with the addition of recombinant BDNF and VEGF molecules (18). As a
result, it has been hypothesized that the differential response in survivability and
resistance to sublethal chronic hypoxia between the CD‐1 and C57BL/6 mouse strains
could be due to a difference in activation HIF1α, and its effector molecules, which
include BDNF and VEGF, as well as SDF‐1.
HIF1α is a transcription factor regulating multiple proteins, including
erythropoietin, glucose transporters, glycolytic enzymes, and VEGF among others, that
are involved in cellular adaptation to hypoxia, (35, 36). Analysis of HIF1α expression
levels in CD‐1 pup brains revealed significantly higher levels of HIF1α expression than in
their C57BL/6 counterparts under normoxic conditions, and comparatively greater drop
in HIF1α levels in C57BL/6 pups in comparison to CD‐1 pups, when reared under hypoxic
conditions, thus resulting in higher levels of HIF1α expression in CD‐1 mice in both
instances. Similarly, BDNF expression levels were also higher in CD‐1 brain lysates
compared to C57BL/6 lysates of mice experiencing hypoxia, with no significant
difference in BDNF levels between mouse strains reared under normoxic conditions.
Interestingly enough, while BDNF levels showed significantly higher expression in
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hypoxic vs. normoxic CD‐1 pups, BDNF expression levels remained essentially
unchanged in C57BL/6 pups between the two conditions. Determination of VEGF‐A165
expression levels using ELISA revealed that, while both strains exhibited an increase in
VEGF‐A165 expression from normoxic‐ to hypoxic‐reared mice, under both conditions CD‐
1 brain lysates showed a significantly higher VEGF‐A165 expression rate than their
C57BL/6 counterparts. Lastly, the same pattern held true for SDF‐1 expression levels,
wherein normoxic CD‐1 brain lysates showed a higher level of expression than normoxic
C57BL/6 brain lysates, and hypoxic CD‐1 brain lysates showed a higher level of
expression than hypoxic C57BL/6 brain lysates (Fig 4). Similar findings in the expression
of these proteins in NPCs harvested from P1 CD‐1 and C57BL/6 pups and grown under
normoxic and hypoxic conditions were also found in cell culture (9).
Together, these data are consistent with the potential molecular mechanism
which governs the differential ability to recover from chronic hypoxia between the CD‐1
and C57BL/6 mouse strains, wherein the hypoxemic insult activates HIF‐1α, which in
turn upregulates expression of BDNF, VEGF, and SDF‐1. These three signaling cascades
all converge on the PI3K/AKT signal transduction pathway, which serves to activate
endothelial nitric oxide synthase (eNOS). Increased NO levels then further upregulate
HIF‐1α expression, closing the positive feedback loop, and serve to stimulate NSC
proliferation and survival (Fig 5) (9, 37‐43). As a result, fetal or neonatal expression
levels of BDNF, VEGF, and SDF‐1 could be prime candidates for potential molecular
biomarkers that could predict a neonate’s ability to return to baseline after experiencing
prolonged hypoxia as a consequence of prematurity.
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In addition, recent data has shown that expression levels of BDNF and SDF‐1
could be also affected by the presence or absence of specific single nucleotide
polymorphisms (SNPs) within the genome. The BDNF val66met polymorphism (rs6265)
is a G to A variant of the BDNF gene at nucleotide 196, which produces an amino acid
substitution in the 5’ pro‐BDNF region that affects the protein’s intracellular processing
and secretion. One study showed hippocampal neurons transfected with metBDNF‐GFP
recombinant proteins exhibited abnormal localization of the protein to the neuronal cell
bodies in the peri‐nuclear region versus a more diffuse distribution throughout the cell
body and extending into dendritic processes that occurred with the valBDNF‐GFP
variant. Moreover, BDNF secretion studies in these neurons showed a significant
decrease in the activity‐dependent secretion of BDNF in neurons transfected with the
metBDNF gene compared to valBDNF variant, upon nerve stimulation (19). The
mechanism responsible for this difference is thought to be rooted in the disruption of
interaction between pro‐BDNF and the sortilin protein, which is responsible for sorting
BDNF into the regulated secretory pathway (20).
A less‐well established link between the presence of a polymorphism and its
effect on protein expression exists in SDF‐1. The G801A (rs1801157) polymorphism is
located in the 3’ untranslated region of the SDF‐1 (also known as CXCL12) gene that has
been linked to a change in a variety of different disease susceptibilities among
individuals (21‐23). A genetic association analysis of 2857 of patients enrolled in five
AIDS cohort studies revealed that individuals homozygous for the G801A polymorphism
infected with HIV had a significant delay in the onset of AIDS. This observation is
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thought to be rooted in increased SDF‐1 expression levels, which bind SDF‐1’s cognate
receptor, CXCR4, thereby decreasing the ability of HIV viral particles from infecting new
CD4 T‐cells (which also utilize the CXCR4 receptor) (22). A later study measuring plasma
SDF‐1 levels in HIV positive and HIV negative patients showed significantly decreased
levels in patients homozygous for the G801A SNP (23). Similarly, Florence et al. found
that patients positive for the G801A polymorphism on either one or both alleles had an
increased rate of extramedullary metastasis in acute myeloid leukemia—a process
which is thought to be linked with decreased expression levels of SDF‐1 (21).
Consequently, though the effects of the G801A SNP on SDF‐1 expression are not well
established, its presence appears to play a role in a variety of disease processes. As a
result, both the G196A SNP in BDNF and the G801A SNP in SDF‐1 have the potential to
be genetic biomarkers that would be predictive of an individual’s ability to recover from
hypoxia induced damage, and should be investigated further.
To assess the utility of BDNF expression levels and the presence of the G196A
BDNF and G801A SDF‐1 SNPs in predicting neonatal outcomes, our group analyzed the
cord blood of 53 premature singleton neonatal patients born to mothers at Yale New
Haven Hospital. BDNF expression levels in a subset of these patients was determined
using a quantitative ELISA assay, which were then compared to the presence or absence
of a variety of neonatal complications associated with premature birth and hypoxia
(Table F). Of the complications analyzed, the only one to yield statistical significance was
death, which was surprisingly associated with an increased average BDNF level in
neonates who died versus those who survived. This seemingly paradoxical outcome is
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likely a statistical anomaly that is due to the fact that out of the 23 patients that were
analyzed, only 3 died. Moreover, one of these three patients exhibited BDNF levels
more than two‐fold higher than the other two, thereby significantly skewing the average
for the entire group.
Both presumed early onset neonatal sepsis and clinical early onset neonatal
sepsis (EONS) trended towards significance, with p‐values <0.10. The average BDNF
expression levels for patients experiencing either presumed or clinical EONS was 30%
lower than in patients who did not experience these complications. EONS is associated
with a variety of multi‐systemic complications including respiratory distress,
dehydration secondary to diarrhea and vomiting, and apnea, all of which have the
potential to decrease perfusion and/or oxygenation of tissues (44). Though poorly
understood, members of the neurotrophin family, including nerve growth factor (NGF)
and BDNF have been shown to be expressed in a variety of non‐neuronal systems
throughout development, including the cardiovascular, endocrine, reproductive, and
immune systems, with the highest levels of BDNF mRNA expressed in the heart, spleen,
and lung tissues (45, 46). Given the key role BDNF plays in protecting against hypoxia‐
induced cellular damage as part of the HIF‐1α response, and the fact that the diagnosis
of neonatal sepsis most often occurs based on clinical symptoms (rather than positive
blood cultures), it would be reasonable to extrapolate that premature infants who
exhibit higher baseline levels of BDNF would be better protected against hypoxia
induced damage and would therefore be less likely to acquire the diagnosis of sepsis.
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Analysis of the development of bronchopulmonary dysplasia (BPD) also showed
a trend towards significance with regards to BDNF expression levels. Neonates who
developed BPD had on average nearly a 40% lower BDNF expression level than those
who did not (69.2 vs 114.36 pg/mg, p<0.08). As would be expected, this trend is
consistent with BDNF’s protective properties against hypoxia‐induced damage. The
pathogenesis of BPD is the result of direct airway and parenchymal damage prior to the
maturation of the lungs, and is associated, among other causes, with a variety of
medical interventions such ventilator‐induced lung injury, oxygen toxicity secondary to
O2 supplementation, and exposure to steroids (47). Moreover, as described above,
developing lung tissue is one of the most active areas of transcription of BDNF mRNA
outside of the nervous system, suggesting the importance BDNF may play in proper lung
development. Consequently, premature infants who exhibit higher levels of BDNF at
baseline would be more resilient to the deleterious effects of low O2 associated with
premature birth, and would therefore be less likely to receive potentially harmful
interventions, which would in turn decrease their chances of developing BPD.
The last of the neonatal complications that were analyzed with regards to
baseline BDNF expression levels to show a trend towards significance was the
development of necrotizing enterocolitis (NEC). The average BDNF expression levels of
neonates who developed NEC was less than 60% then that of newborns that did not
develop this complication (74.48 pg/mg versus 124.16 pg/mg, p < 0.09). The
pathogenesis of NEC is primarily due to changes from intestinal infarction, with the
resulting inflammation and reactive tissue repair playing key roles in impairment of
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proper gastrointestinal function (48). Hoehner et al. have shown that BDNF plays a key
role in the development of the enteric nervous system, and is actively expressed in
enteric ganglion cells (EGCs) throughout different stages of development (49). More
recently, Steinkamp et al. have also shown that BDNF secreted by EGCs under
inflammatory conditions plays a significant role in attenuating the EGCs apoptotic
response (50). Thus, once again, it appears that increased baseline levels of BDNF may
serve a protective role in infants from developing one of the complications associated
with prematurity.
Analysis of the presence of possible placental infections and their association
with BDNF levels yielded two statistically significant results (Table F). The development
of both amnionitis and funisitis during the pregnancy was associated with significantly
lower levels of cord blood BDNF detected than was found in the cord blood of patients
who did not develop these infections (92.54 vs 154.92 pg/mg for amnionitis, p‐value
<0.02; 93.83 vs 147.14 pg/mg for funisitis, p‐value 0.03). Moreover, it should be noted,
that although not statistically significant, the average cord blood BDNF levels in patients
who suffered from development of chorionic plate inflammation or choriodeciduitis was
also lower than in patients whose placentas did not show signs of infection on
histological analysis. A recent study on the differential expression of BDNF in the human
placenta during the third trimester showed that BDNF and its cognate receptors are
expressed throughout the membranous chorion, trophoblast, and endothelium.
Moreover, this expression was higher in placentas of mothers experiencing
preeclampsia, normotensive small for gestational age placentas, and the placentas of
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the small twin of discordant twin pregnancies. Fujita et al. went on demonstrate that
BDNF had anti‐apoptotic effects against oxidative stress in the choriocarcinoma cell line
(JEG‐3), suggesting that BDNF plays a protective role in human villous tissue under a
variety of unfavorable conditions in utero (51). These findings are compatible with our
observation that the development and progression of more severe inflammatory
processes in the placenta is associated with lower BDNF expression levels.
Surprisingly, of the complications analyzed, the three dealing with the
developing nervous system (development of interventricular hemorrhage, retinopathy
of prematurity, and periventricular leukomalacia) did not reveal statistically significant
associations with cord blood BDNF levels. One possible explanation for this
phenomenon is the relatively high amount of comorbidities that are present in the
premature infants analyzed, the effects of which may be obscuring the link between
BDNF levels and the development of complications. Upon more careful analysis of
infants who developed IVH, for instance, we are able to tease out the link by separating
the patients into three distinct groups: (1) infants who did not develop IVH, (2) infants
who did not develop IVH, but did have EONS, and lastly (3) infants who had IVH.
Analysis of these three groups revealed that infants who were IVH neg/EONS neg had a
nearly two fold higher baseline BDNF expression level than infants who were IVH
neg/EONS pos (p = 0.021), and infants who were IVH neg/EONS neg had a 44% higher
BDNF expression levels than children who were IVH pos (p = 0.054, Fig 3). As previously
described, BDNF may play a role in the body’s response to the development of EONS.
Thus, given the limited number of patients whose BDNF levels were able to be assessed,
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outside factors such as the presence EONS in the patient may obscure less robust
associations between baseline BDNF levels and development of certain complications.
As a result, further studies with increased number of subjects are necessary to better
elucidate the presence of these links.
Next, we analyzed for the presence of the G196A BDNF SNP in the cord blood of
fifty three premature neonates using both RFLP assays and direct Sanger sequencing of
fetal DNA. The prevalence of the G196A SNP did not significantly differ among patients
with respect to maternal age, race, or gender, and was not found to be associated with
any statistically significant changes in neonatal outcomes (Tables B and C). Pregnancy
outcomes that appeared to trend towards significance included median gestational age
at delivery (p = 0.065) and median birthweight (p = 0.099). However, even among these
two outcomes, the interquartile range between neonates with the G‐allele vs the A‐
allele, had substantial overlap. Of the neonatal characteristics analyzed, both median
cord blood arterial pH and culture positive EONS appeared to trend towards
significance, with p‐values of 0.096 and 0.077, respectively. In light of the previously
discussed protective roles that BDNF may play as part of the HIF‐1α signaling pathway,
which serves to blunt the negative effects of hypoxia, our observation of lower levels of
acidosis associated with the G‐allele is logical. However, given that our analysis for the
presence of the G196A SNP did not yield any statistically significant correlation with
baseline cord blood BDNF expression levels, any such results should be interpreted with
caution.
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There are many possible reasons for the discordance between the presence of
the G196A SNP in a patient and its lack of correlation to the detected cord blood BDNF
levels. The path from gene transcription to protein expression is riddled with many
different regulatory pathways, and the SNP’s effect on secretion is just one of them.
Recently, Verhmehren‐Schmaedick et al. have shown that loss of the methy‐CpG‐
binding protein 2 (MeCP2) transcription factor, that occurs in Rett syndrome, results in
the blunting of the hypoxia‐induced increase in BDNF transcript and protein expression
levels in the pons and medulla of mice lacking MeCP2 (52). This finding suggests that a
variety of unaccounted for factors affecting BDNF expression levels, which may vary
among the patients studied, may be obscuring the effect of G196A SNP on BDNF
expression. Alternatively, the study by Egan et al. has shown that the presence of the
G196A SNP affects nerve depolarization‐induced secretion in cultured hippocampal
neurons, but does not have any effect on the constitutive secretion of BDNF (19). Since
the nerve‐stimulatory pathway of BDNF secretion differs from that of the hypoxia‐
induced pathway, the effects of the G196A SNP on BDNF expression under hypoxic
conditions may in fact be different than we hypothesized. Lastly, Chen et al. have shown
that the effects of the G196A polymorphism on BDNF secretion appears to be specific to
neural tissue, and while endothelial cells and vascular smooth muscle cells secrete BDNF
at levels comparable with the CNS at baseline (53‐55), the secretion of BDNF by these
cell types was not affected by the presence of the G196A SNP (56). Consequently, since
we are determining BDNF protein levels as they are detected in samples of cord blood, it
is likely that the BDNF levels that are present overwhelmingly represent active secretion
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by the developing cardiovascular system, which would mask any variations in BDNF
expression localized to the nervous system.
The presence of the G801A SDF‐1 SNP was also analyzed in duplicate using both
RFLP and direct Sanger sequencing analysis, in the same fifty three premature neonates
as the G196A SNP. Once again, the prevalence of the G801A SNP did not significantly
differ among patients with respect to maternal age, race, or gender (Table D). Analysis
of neonatal outcomes and placental inflammation yielded a significantly greater
percentage of premature neonates with the G allele developing clinical EONS (p<0.04),
and choriodeciduitis in the fetal placenta (p<0.04), with a trend towards significance in
the development of chorionic plate inflammation (p<0.09) (Table E). All other outcome
measures did not yield any statistically significant results. The importance of the role
SDF‐1 plays in the immune response through its effects on leukocyte recruitment,
migration, and adhesion has been well established (57). Moreover, SDF‐1/CXCR4
signaling has been implicated in modulating the materno‐fetal immunological tolerance
in all three semesters of gestation that is essential for fetal survival (58). Consequently,
differences in SDF‐1 expression levels that result from the presence or absence of the
G801A SNP may be responsible for the correlation between the presence of the A‐allele
and a decreased inflammatory response. Furthermore, such an association would be
consistent with previous reports of the G801A SNP being linked to lower SDF‐1
expression levels (21, 23). However, direct measurement of SDF‐1 serum protein levels
would be necessary to further validate this link.
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There are number of factors in this study that limit the generalizability of our
results, and thus require further investigation. First, the study was limited by the
number of patients that were used to assess the links between presence of SNPs, BDNF
protein expression levels, and neonatal outcomes. The number of neonates examined
served well as a preliminary study to support the link between higher BDNF protein
expression levels and more positive neonatal incomes. However, more patients would
need to be analyzed to move the results from trends to statistical significance.
Moreover, although the available literature supports a possible link between the
presence of particular SNPs and outcomes, this relationship is affected by a multitude of
outside factors, which would require several thousand more patients to be examined
before sufficient power can be reached to confidently support or reject such a
relationship. Another important limitation to this study is the non‐specific nature of the
source of blood from which protein expression levels were determined. Cord blood was
obtained from the umbilical veins of patients upon delivery. While easily accessible, this
source represents a mixture of proteins secreted throughout the body, with perhaps an
overrepresentation of secretions from the fetal vasculature and the placenta, thus
obscuring localized changes in expression that may be occurring in more isolated tissues
like the nervous system. It would be interesting to examine differences in protein
expression levels obtained from a variety of sites, such as both the arterial and venous
systems, and see if any significant differences result. Lastly, multiple studies of the
G801A SDF‐1 SNP have suggested that the presence of the A‐allele has no effect on SDF‐
1 protein expression levels, but it is in fact the presence of a number of other SNPs that
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are in linkage disequilibrium with the G801A SNP, which affect protein expression levels
and disease outcomes (59, 60). Consequently, it important to consider the effects of
other known SNPs in both BDNF and SDF‐1 genes that may be in linkage disequilibrium
with the SNPs examined in this study, as it is they that might ultimately be responsible
for (and be most useful in predicting) neonatal response to hypoxia induced damage.
In conclusion, the ability to be able to accurately predict both short term and
long term clinical outcomes for premature infants promises to hold much benefit. From
rationing out limited resources to patients who would benefit from them the most, to
avoiding unnecessary long term and serious complications, being able to separate
infants who need medical intervention from those who will recover on their own would
result in millions of dollars in saving and greatly decrease morbidity. Moreover, such a
tool would also allow us to evaluate the efficacy of novel therapies by helping us
separate the benefits gained through a given intervention from the natural progression
of disease that would have occurred even without clinical interference. Genetic and
molecular biomarkers in cord blood, which is easily obtainable at birth, are prime
candidates to enable us to accomplish this task.
Here we report preliminary exploration of three such potential biomarkers: the
presence of G196A SNP in the BDNF gene, the presence of G801A SNP in the SDF‐1
gene, and BDNF protein expression levels present in umbilical cord venous system. Of
these, direct measurement of protein levels in cord blood appear to be most promising,
at least in the short term. The effects of an individual SNP on neonatal outcomes do not
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appear strong enough to discern any clinically useful stratification among patients on
their own. However, there are many different candidates that are yet to be examined,
that together have the potential to be treasure trove of prognostic biomarkers. Our
initial attempts at characterizing a number of SNPs associated with the VEGF gene (data
not shown) proved unsuccessful due to technical difficulties in amplifying the gene’s G‐C
rich promoter sequence in time for this manuscript. However, further investigation of
both VEGF associated SNPs and cord blood protein levels is necessary, given the key role
VEGF plays in stabilizing the neurovascular niche and overall vascular development/
homeostasis. Moreover, given the disproportionate costs associated with long‐term
complications of prematurity, further studies with long term follow up over a period of
decades would also be useful. Nevertheless, despite the limitations of the current study,
this preliminary foray into improving our abilities at predicting neonatal recovery from
hypoxia induced damage associated with prematurity helps pave the way into a line of
inquiry that has the potential to revolutionize neonatal medicine
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Maternal Age, years†

27 [23-33]

31 [23.75-33.25

0.459

Gravidity

3 [2-4]

3 [2-3.25]

0.898

Parity†

1 [0-2]

1 [0.75-2]

0.426

†

Race‡

0.876

Caucasian

14 (32)

4 (40)

African American

19 (44)

3 (30)

Hispanic

7 (16)

2 (20)

3 (7)

1 (10)

29 (67)

6 (60)

0.719

30 (70)

6 (60)

0.709

3 (7)

1 (10)

0.579

42 (98)

10 (100)

1.000

Antibiotics

40 (93)

8 (80)

0.235

§

Tocolysis

20 (47)

3 (30)

0.484

Magnesium sulfate§

16 (37)

1 (10)

0.140

9 (21)

4 (40)

0.237

Other
Non-Causasian race

§

Ruptured Membranes

§

Clinical chorioamnionitis§
Antenatal Drug treatments/exposure
Steroids§
§

Progesterone during pregnancy

§

Pregnancy outcome characteristics
Indicated preterm delivery§

31 (72)

4 (40)

0.071

Gestational age at delivery, weeks†

26.2 [25.1-30]

30.15 [27.43-32.7]

0.065*

Birthweight, grams†

930 [780-1450]

1460 [1114-1800]

0.099*

6 [4-8]

6.5 [4.75-8.25]

0.646

8 [7-9]

8 [8-9]

0.756

22 (51)

5 (50)

1.000

8 (19)

1 (10)

1.000

19 (45)

3 (30)

0.488

Apgar score at 1 minute

†

Apgar score at 5 minutes
1 min Apgar <7

§

5 min Apgar <7§
Newborn male gender

§

†

Table B. Pre-natal maternal and peri-natal infant characteristics. Data analyzed with respect to
presence of either the G- or the A-allele in the BDNF gene amplified from venous cord blood.
† Data analyzed by Mann Whitney Rank Sum test and presented as median [interquartile range].
‡ Data analyzed by Chi Square Analysis and presented as n (%).
§ Data analyzed by Fischer’s exact tests and presented as n (%).
* Data trending towards significance (p < 0.10).
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Presence of BDNF G to A SNP
G (n=43)

P

A (n=10)

Umbilical cord blood analysis
Arterial pH†

7.32 [7.29-7.35]

7.30 [7.28-7.31]

0.096*

Arterial base deficit

4.55 [3.05-6.08

4.8 [3.35-6.80]

0.747

Venous pH†

7.38 [7.34-7.40]

7.35 [7.33-7.39]

0.159

3.9 [2.1-7.25]

3.5 [1.9-8.0]

1.000

Chorionic plate inflammation, stages II-III§

33 (79)

5 (50)

0.109

Amnionitis, stages 2-4§

25 (60)

4 (40)

0.307

Choriodeciduitis, stages 2-4§

36 (86)

7 (70)

0.349

Funisitis, stages 1-4

22 (52)

5 (50)

1.000

SDF-1 T-allele§

9 (21)

4 (40)

0.237

Innterventricular Hemorrhage§

10 (24)

1 (11)

0.663

Brochopulmonary Dysplasia§

7 (18)

1 (10)

1.000

Necrotizing Enterocolitis§

5 (12)

1 (10)

1.000

†

Venous base deficit

†

Placental histological analysis

§

Neonatal Complications

Retinopathy of Prematurity

15 (36)

2 (22)

0.699

Periventricular Leukomalacia§

4 (10)

1 (11)

1.000

Presumed EONS

§

28 (65)

6 (60)

1.000

Culture positive (confirmed) EONS§

3 (7)

3 (30)

0.077*

Clinical EONS§

14 (33)

5 (50)

0.467

Death§

4 (10)

0 (0)

0.576

Any Adverse Outcome§

17 (40)

3 (30)

0.722

§

Table C. Post-natal clinical characteristics of the newborn infants. Data analyzed with respect to presence of either the G- or the A-allele in the BDNF gene amplified from venous cord blood.
† Data analyzed by Mann Whitney Rank Sum tests and presented as median [interquartile range].
§ Data analyzed by Fischer’s exact tests and presented as n (%).
* Data trending towards significance (p < 0.10).
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Presence of SDF-1 G to A SNP
G (n=40)

A (n=13)

P

Maternal demographic and clinical characteristics at enrollment (amniocentesis)
Maternal Age, years†
Gravidity

†

Parity

†

29.5 [23.25-34]

25 [22.5-31.5]

0.246

3 [2-4]

2 [1.5-3.5]

0.440

1 [0-2]

1 [0-2]

0.596

Race

0.165

‡

Caucasian

11 (27.5)

7 (53.8)

African American

19 (47.5)

3 (23.1)

6 (15)

3 (23)

4 (10)

0 (0)

Hispanic
Other
Non-Causasian race

29 (72.5)

6 (46.15)

0.101

Ruptured Membranes§

28 (70)

8 (61.5)

0.734

Clinical chorioamnionitis§

3 (7.5)

1 (7.7)

1.000

Steroids§

40 (100)

12 (92.3)

0.245

Antibiotics§

37 (92.5)

11 (84.6)

0.586

16 (40)

7 (53.8)

0.522

12 (30)

5 (38.5)

0.734

10 (25)

3 (23.1)

1.000

26 (65)

9 (69.2)

1.000

§

Antenatal Drug treatments/exposure

Tocolysis

§

Magnesium sulfate

§

Progesterone during pregnancy§
Pregnancy outcome characteristics
Indicated preterm delivery§
Gestational age at delivery, weeks

†

Birthweight, grams†
Apgar score at 1 minute†
Apgar score at 5 minutes
1 min Apgar <7§
5 min Apgar <7§
Newborn male gender

§

†

26.8 [25.3-30.2]

26.2 [25.1-33.2]

0.764

1025 [785-1487.5]

920 [805-2000]

0.577

6 [4-8]

8 [3.5-8.5]

0.699

8 [7-9]

8 [6.5-9]

0.811

21 (52.5)

6 (46.2)

0.757

6 (15)

3 (23)

0.672

17 (42.5)

5 (41.7)

1.000

Table D. Pre-natal maternal and peri-natal infant characteristics. Data analyzed with respect to
presence of either the G- or the A-allele in the SDF-1 gene amplified from venous cord blood.
† Data analyzed by Mann Whitney Rank Sum test and presented as median [interquartile range].
‡ Data analyzed by Chi Square Analysis and presented as n (%).
§ Data analyzed by Fischer’s exact tests and presented as n (%).
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Presence of SDF-1 G to A SNP
G (n=40)

P

A (n=13)

Umbilical cord blood analysis
Arterial pH†

7.315 [7.293-7.350]

7.31 [7.285-7.327]

0.449

4.2 [3.05-6.05]

5.1 [3.325-6.825]

0.683

7.365 [7.338-7.40]

7.380 [7.367-7.39]

0.406

3.9 [1.9-7.8]

3.45 [2.3-5.25]

0.688

Chorionic plate inflammation, stages II-III§

31 (79.5)

7 (53.8)

0.086*

Amnionitis, stages 2-4

Arterial base deficit

†

Venous pH†
Venous base deficit†
Placental histological analysis

24 (61.5)

5 (38.5)

0.201

Choriodeciduitis, stages 2-4§

35 (89.7)

8 (61.5)

0.033**

Funisitis, stages 1-4§

22 (56.4)

5 (38.5)

0.343

§

Neonatal Complications
6 (15)

4 (30.8)

0.237

Innterventricular Hemorrhage§

9 (22.5)

2 (18.2)

1.000

Brochopulmonary Dysplasia§

5 (13.5)

3 (27.3)

0.361

Necrotizing Enterocolitis

5 (12.5)

1 (8.3)

1.000

12 (30)

5 (45.5)

0.472

BDNF A-Allele§

§

Retinopathy of Prematurity§
Periventricular Leukomalacia§

4 (10)

1 (9.1)

1.000

Presumed EONS§

26 (65)

8 (61.5)

1.000

Culture positive (confirmed) EONS§

6 (15)

0 (0)

0.316

Clinical EONS§

18 (45)

1 (8.3)

0.037**

3 (7.5)

1 (8.3)

1.000

14 (35)

6 (50)

0.500

Death§
Any Adverse Outcome

§

Table E. Post-natal clinical characteristics of the newborn infants. Data analyzed with respect to presence
of either the G- or the A-allele in the SDF-1 gene amplified from venous cord blood.
† Data analyzed by Mann Whitney Rank Sum tests and presented as median [interquartile range].
§ Data analyzed by Fischer’s exact tests and presented as n (%).
* Data trending towards significance (p < 0.10).
** Data statistically significance (p < 0.05).
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Presence of Complication
YES

NO

P

Placental histological analysis
Chorionic plate inflammation, stages II-III‡

112.06 ± 16.62

145.08 ± 20.94

0.192

Amnionitis, stages 2-4‡

92.54 ± 15.95

154.92 ± 21.41

0.014**

Choriodeciduitis, stages 2-4‡

114.50 ± 15.75

140.63 ± 33.65

0.271

Funisitis, stages 1-4‡

93.83 ± 16.14

147.14 ± 21.98

0.030**

116.31 ± 15.62

110.23 ± 25.19

0.443

Neonatal Complications
Presence of G196A SNP‡
Innterventricular Hemorrhage

‡

Brochopulmonary Dysplasia‡
Necrotizing Enterocolitis‡
Retinopathy of Prematurity‡
Periventricular Leukomalacia

109.46 ± 29.56

118.75 ± 15.0

0.379

69.2 ± 8.45

114.36 ± 14.89

0.079*

74.48 ± 8.88

124.16 ± 16

0.089*

108.83 ± 16.38

122.82 ± 23.38

0.312

149.8 ± 54.08

108.3 ± 12.78

0.132

Presumed EONS‡

104.29 ± 17.05

147.33 ± 17.7

0.089*

Culture positive (confirmed) EONS‡

118.16 ± 45.13

114.78 ± 13.51

0.461

Clinical EONS‡

95.66 ± 19.78

141.33 ± 16.28

0.051*

Death‡

183.43 ± 57.93

105.33 ± 12.63

0.027**

Any Adverse Outcome‡

120.58 ±18.16

107.64 ± 22.27

0.329

‡

Table F. BDNF protein expression levels. Average protein levels given with respect to presence or absence of complication.
‡ Data analyzed by 1-tailed student t-tests and presented as mean BDNF ± SEM.
* Data trending towards significance (p < 0.10).
** Data statistically significance (p < 0.05).
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(a)

(b)

(c)

(d)

Figure 1. Identifcation of G196A SNP in the BDNF gene. (a) Representative gel demonstrating BDNF
PCR product. (b) Representative gel demonstrating cleavage products following digestion of PCR
product by AflIII and PmlI restriction endonucleases. Sample heterozygous for the A-allele is marked
with an arrow. (c) Representative trace sequence of BDNF gene homozygous for the G-allele at position 196 (arrow). (d) Representative trace sequence of the BDNF gene heterozygous for the A-allele at
position 196 (arrow).
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(a)

(b)

(c)

(d)

Figure 2. Identifcation of G801A SNP in the SDF-1 gene. (a) Representative gel demonstrating SDF-1
PCR product. (b) Representative gel demonstrating cleavage products following digestion of PCR
product by NciI restriction endonuclease. Samples heterozygous for the A-allele are marked with
arrows. (c) Representative trace sequence of SDF-1 gene homozygous for the G-allele at position 801
(arrow). (d) Representative trace sequence of the SDF-1 gene heterozygous for the A-allele at position
801 (arrow).
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BDNF levels
(a)

250

BDNF levels
(b)

250

p = 0.054
200

200

p = 0.379

pg/mg

150

pg/mg

150

p = 0.021

100

100

50

50

0

0

No IVH

Grd 3-4 IVH

No IVH

EONS no IVH Grd 3-4 IVH

Figure 3. Average BDNF expression levels with respect to presence or absence of grade 3 or 4 intraventricular hemorrhage (IVH). (a) BDNF levels in patients seperated into two groups, without regard for
presence or absence of other co-morbidities. (b) BDNF levels in patients seperated into three groups,
demonstrating the development of early onset neonatal sepsis (EONS) as a possible confounder for analyzing the relationship between BDNF expression levels and development of IVH (vertical bars represent
standard error).
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A

B

C

D

Figure 4. Adapted with permission from [9]. P11 C57BL/6 brain homogenates exhibit distinct normoxic and hypoxic selected transcription
factor and growth factor expression levels compared with CD-1 pups.
Analysis of expression levels of (A) HIF1α, (B) BDNF, (C) VEGF, and (D)
SDF-1 in C57BL/6 (open boxes) and CD-1 (shaded boxes) brain homogenates under normoxic (NX) and hypoxic (HX) conditions (vertical bars
represent standard deviations; n = 3).
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Figure 5. Reproduced with permission from [9]. Working
model of the signaling pathway components that are differentially regulated in C57BL/6 and CD-1 pup brain tissues and
cultured NPCs under normoxic and hypoxic conditions.
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